FDA Approves Inavolisib for PIK3CA-Mutated HR+/HER2− MBC

In the approval trial, Genentech's PI3K inhibitor doubled progression-free survival compared with placebo.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-approves-inavolisib-hr-her2%E2%88%92-advanced-breast-2024a1000ilk?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost